Pamabrom
White to off-white solid powder
Others
Pamabrom is a diuretic drug that is commonly used to relieve symptoms of premenstrual syndrome (PMS) and menstrual cramps. It is a member of the xanthine family of drugs and works by increasing urine output, which helps to reduce bloating and fluid retention.
348.2 g/mol
348.2 g/mol
Formulation:
348.2 g/mol
Source:
Usage:
Pamabrom
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog Number: BT-278676
CAS Number: 606-04-2
Molecular Formula: C11H18BrN5O3
Molecular Weight: 348.2 g/mol
Purity: ≥ 98%
Inventory: In Stock
| Size | SKU | Price | |
|---|---|---|---|
| 100mg | bt-278676-100mg | $302.00 | |
| 1g | bt-278676-1g | $1,051.08 | |
| 5g | bt-278676-5g | $2,317.23 |
| CAS Number | 606-04-2 |
|---|---|
| Product Name | Pamabrom |
| Molecular Formula | C11H18BrN5O3 |
| Molecular Weight | 348.2 g/mol |
| Appearance | White to off-white solid powder |
| InChI | InChI=1S/C7H7BrN4O2.C4H11NO/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14;1-4(2,5)3-6/h1-2H3,(H,9,10);6H,3,5H2,1-2H3 |
| InChI Key | ATOTUUBRFJHZQG-UHFFFAOYSA-N |
| IUPAC Name | 2-amino-2-methylpropan-1-ol;8-bromo-1,3-dimethyl-7H-purine-2,6-dione |
| Canonical SMILES | CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br |
| Description | Pamabrom is a diuretic drug that is commonly used to relieve symptoms of premenstrual syndrome (PMS) and menstrual cramps. It is a member of the xanthine family of drugs and works by increasing urine output, which helps to reduce bloating and fluid retention. |
| Method of Synthesis or Extraction | Pamabrom can be synthesized using a variety of methods, including the reaction of theophylline with bromine or the reaction of caffeine with bromine in the presence of sodium hydroxide. The efficiency and yield of each method vary depending on the reaction conditions and the purity of the starting materials. Environmental and safety considerations must also be taken into account when synthesizing pamabrom, as some of the starting materials and reaction products may be hazardous to human health or the environment. |
| Chemical Structure and Biological Activity | The chemical structure of pamabrom consists of a xanthine core with a bromine atom attached to one of the nitrogen atoms. The mechanism of action of pamabrom involves inhibition of the reabsorption of sodium and chloride ions in the kidneys, which leads to increased urine output. Pamabrom has been shown to have a high affinity for adenosine receptors, which may contribute to its diuretic and other biological effects. The bioactivity and potency of pamabrom depend on the dose and route of administration, as well as individual factors such as age, sex, and health status. |
| Biological Effects | Pamabrom has been shown to have a variety of biological effects on cell function and signal transduction, including modulation of ion channels, enzymes, and second messenger systems. It has also been investigated for its potential therapeutic and toxic effects in various animal and human studies. Some of the potential therapeutic effects of pamabrom include relief of Pamabrom symptoms, reduction of blood pressure, and improvement of kidney function. However, pamabrom may also have potential side effects such as dehydration, electrolyte imbalances, and interactions with other drugs. |
| Applications | Pamabrom has been used in medical research for its role in drug development, clinical trials, and findings related to its benefits and potential side effects. It has also been studied in environmental research for its effects on ecosystems, role in pollution management, and sustainability and environmental impact. In industrial research, pamabrom has been used in manufacturing processes to improve product quality and efficiency, with health and safety considerations being a major concern. |
| Future Perspectives and Challenges | Despite its potential benefits, there are still some limitations in the use and study of pamabrom, including its potential side effects and interactions with other drugs. Possible solutions and improvements include the development of more selective and potent analogs of pamabrom, as well as the use of new technologies such as nanotechnology and gene therapy. Future trends and prospects in the application of pamabrom in scientific research include its potential use in the treatment of other conditions such as heart disease and cancer, as well as its role in personalized medicine and drug delivery systems. However, there are also challenges related to the regulation and safety of pamabrom, as well as the ethical and social implications of its use. |
| Other CAS Number | 606-04-2 |
| Pictograms | Irritant |
| Shelf Life | >2 years if stored properly |
| SMILES | CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br |
| Solubility | Soluble in DMSO |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Synonyms | 2-amino-2-methyl-1-propanol-8-bromotheophyllinate Maximum Strength Aqua-Ban pamabrom |
| Reference | 1: Abdelaleem EA, Naguib IA, Hassan ES, Ali NW. HPTLC and RP-HPLC methods for simultaneous determination of Paracetamol and Pamabrom in presence of their potential impurities. J Pharm Biomed Anal. 2015 Oct 10;114:22-7. doi: 10.1016/j.jpba.2015.04.043. Epub 2015 May 8. PubMed PMID: 26001162. 2: Shah U, Kavad M, Raval M. Development and Validation of Stability-indicating RP-HPLC Method for Estimation of Pamabrom in Tablets. Indian J Pharm Sci. 2014 May;76(3):198-202. PubMed PMID: 25035530; PubMed Central PMCID: PMC4090826. 3: Tan DS, Sklar GE. Erythema multiforme secondary to dimenhydrinate in a patient with previous similar reactions to pamabrom. Ann Pharmacother. 2014 Mar;48(3):425-8. doi: 10.1177/1060028013518728. Epub 2014 Jan 6. PubMed PMID: 24396093. 4: El-Houssini OM. RP-LC and TLC Densitometric Determination of Paracetamol and Pamabrom in Presence of Hazardous Impurity of Paracetamol and Application to Pharmaceuticals. Anal Chem Insights. 2013 Sep 5;8:73-81. doi: 10.4137/ACI.S12349. eCollection 2013. PubMed PMID: 24046511; PubMed Central PMCID: PMC3771670. 5: Lee S, Yang Y, Fishman D, Banaszak Holl MM, Hong S. Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. J Phys Chem B. 2013 Aug 8;117(31):9233-40. doi: 10.1021/jp4055186. Epub 2013 Jul 26. PubMed PMID: 23848376; PubMed Central PMCID: PMC3784653. 6: Ortiz MI. Primary dysmenorrhea among Mexican university students: prevalence, impact and treatment. Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1):73-7. doi: 10.1016/j.ejogrb.2010.04.015. Epub 2010 May 15. PubMed PMID: 20478651. 7: Ortiz MI, Rangel-Flores E, Carrillo-Alarcón LC, Veras-Godoy HA. Prevalence and impact of primary dysmenorrhea among Mexican high school students. Int J Gynaecol Obstet. 2009 Dec;107(3):240-3. doi: 10.1016/j.ijgo.2009.07.031. Epub 2009 Aug 27. PubMed PMID: 19716130. 8: Min JA, Kim HS, Kim HO, Park YM. Fixed drug eruption caused by pamabrom. Clin Exp Dermatol. 2009 Oct;34(7):e455-6. doi: 10.1111/j.1365-2230.2009.03501.x. Epub 2009 Aug 14. PubMed PMID: 19681920. 9: Ortiz MI, Fernández-Martínez E, Pérez-Hernández N, Macías A, Rangel-Flores E, Ponce-Monter H. Patterns of prescription and self-medication for treating primary dysmenorrhea in a Mexican population. Proc West Pharmacol Soc. 2007;50:165-7. PubMed PMID: 18605257. 10: Swanson JK, English JC 3rd. Serum sickness-like reaction to Pamabrom. J Drugs Dermatol. 2006 Mar;5(3):284-6. PubMed PMID: 16573265. 11: Di Girolamo G, Sánchez AJ, De Los Santos AR, González CD. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert Opin Pharmacother. 2004 Mar;5(3):561-70. Review. PubMed PMID: 15013925. 12: Kauppinen K. Fixed drug eruptions and oral rechallenge. Cleve Clin J Med. 1991 Jan-Feb;58(1):64-5. PubMed PMID: 1829986. 13: Nedorost S, Taylor JS, Camisa C, Tomecki KJ, Helm T, Durkin WJ. Fixed drug eruption from pamabrom. Cleve Clin J Med. 1991 Jan-Feb;58(1):33-4. PubMed PMID: 1829985. 14: IANIUK VS. [The use of syncol in surgical practice]. Probl Gematol Pereliv Krovi. 1960 Aug;5:61-2. Russian. PubMed PMID: 13717260. 15: DOHERTY JE, BEARD OW. A study of diuretic action of pamabrom (2-amino-2-methyl-propanol-1-8-bromotheophylline) in cardiac failure. Am Heart J. 1953 Aug;46(2):288-90. PubMed PMID: 13080166. |
| PubChem Compound | Pamabrom |
| Last Modified | May 30 2023 |